Cardiomyopathy is a common adverse effect of chemotherapeutic agents (i.e., trastuzumab and doxorubicin) for BC (90–92), which may partially explain why IGLC2 is related to HCM, DCM, and ARVC. Here, IGLC2 is linked to familial dilated cardiomyopathy.